Logo

American Heart Association

  14
  0


Final ID: Tue095

ALY688 Protects Against Myocardial Ischemia-Reperfusion Injury via Direct Effects and Rab8a-dependent Extracellular Vesicles

Abstract Body: Introduction/Background: Ischemia-reperfusion (IR) injury is a primary driver of post-infarction morbidity. While adiponectin is cardioprotective, its clinical use is hindered by its complex molecular structure. ALY688 is a novel, synthetic adiponectin receptor agonist designed for clinical translation.
Research Questions/Hypothesis: We hypothesized that ALY688 reduces myocardial IR injury by activating intracellular survival pathways and stimulating the release of cardioprotective extracellular vesicles (EVs).
Goals/Aims: To evaluate ALY688’s efficacy in a rat IR model and determine the role of the GTPase Rab8a in EV-mediated signaling.
Methods/Approach: Rats underwent 45-min ischemia followed by reperfusion. ALY688 was administered IV during ischemia and SC for 28 days. In vitro studies used H9c2 and human iPSC-derived cardiomyocytes (iPSC-CMs) under hypoxia-reoxygenation (HR). Proteomics characterized heart tissue and circulating EVs. Rab8a was deleted using CRISPR/Cas9.
Results/Data: ALY688 significantly reduced Troponin-I and infarct size (p<0.05), while preserving ejection fraction (EF) and fractional shortening (FS) at 28 days compared to vehicle. In vitro, ALY688 restored autophagic flux, reduced ROS, and decreased apoptosis. Proteomics revealed that ALY688 maintained Rab8a levels, which were otherwise downregulated by IR. ALY688 increased myocardial and plasma EV abundance; these EVs were enriched in glycolytic and anti-oxidative proteins. Treatment with ALY688-induced EVs protected iPSC-CMs from HR-induced death. Importantly, CRISPR-mediated Rab8a knockout abolished ALY688-induced EV biogenesis and negated the cytoprotective effects of these EVs.
Conclusion(s): ALY688 mitigates IR injury through dual cardioprotective mechanisms: direct effects on cardiomyocytes and a Rab8a-dependent EV signaling axis, making it a promising therapeutic candidate.
  • Sung, Hyekyoung  ( York University , Toronto , Ontario , Canada )
  • Tang, Jialing  ( York University , Toronto , Ontario , Canada )
  • Lei, Yubin  ( York University , Toronto , Ontario , Canada )
  • Li, Ren-ke  ( University Health Network , TORONTO , Ontario , Canada )
  • Wu, Jun  ( University Health Network , TORONTO , Ontario , Canada )
  • Sweeney, Gary  ( York University , Toronto , Ontario , Canada )
  • Author Disclosures:
Meeting Info:

Basic Cardiovascular Sciences 2026

2026

Boston, Massachusetts

Session Info:

Poster Session 2

Tuesday, 07/14/2026 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
Apabetalone Protects Against Heart Failure with Preserved Ejection Fraction by Suppressing Myocardial Inflammation

Costantino Sarah, Nazha Hamdani, Paneni Francesco, Gorica Era, Mohammed Shafeeq, Telesca Marialucia, Mongelli Alessia, Masciovecchio Valeria, Herwig Melissa, Ambrosini Samuele, Ruschitzka Frank

Cardiac Adaptations and Mitochondrial Protection Through Long Noncoding RNAs Regulation in Mice on a Ketogenic Diet

Tran Talan, Robison Lisa, Gurusamy Narasimman, Noto Natalia, Hernandez Ariana, Pulido-correa Victoria, Vogel Chana, Lawrence Zachary, James Shalet, Uribe Iliana, Speth Robert

You have to be authorized to contact abstract author. Please, Login
Not Available